![\"5353](\"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2021\/10\/5353-new20logo-01.png\" "\\"Epilepsy")
<\/p>\n<\/p>\n
DelveInsight’s <\/span>Epilepsy pipeline report<\/strong><\/a> provides comprehensive insights into 70+ companies and 70+ pipeline drugs in the Epilepsy pipeline landscape. It also covers pipeline drug profiles, including clinical and non-clinical stage products, therapeutics by product type, stage, route of administration, and molecule type.<\/span><\/p>\n Some of the Important Findings from the <\/strong>Epilepsy Pipeline Report<\/strong><\/a><\/p>\n Request for the sample to get an overview of pipeline landscape @ <\/span>Epilepsy Pipeline Landscape<\/strong><\/a><\/p>\n Epilepsy Overview<\/strong><\/p>\n Epilepsy is a chronic neurological disorder characterized by recurrent seizures that cause unusual behavior. Because of the various types of seizures, causes, and degrees of severity, it is classified as a spectrum disorder. Epilepsy is a condition in which the function of the brain is disrupted by abnormal or excessive electrical discharges from brain cells.<\/span><\/p>\n Epilepsy Symptoms<\/strong><\/a><\/p>\n Seizures are the most common symptom of Epilepsy; however, some other Epilepsy symptoms include:<\/span><\/p>\n Epilepsy Treatment<\/strong><\/p>\n Although Epilepsy cannot be completely cured, doctors can control seizures with antiepileptic drugs (AEDs). Depending on the symptoms and severity of the condition,<\/span> diet therapy and epilepsy surgery<\/strong> may be recommended for Epilepsy treatment.<\/span><\/p>\n Know more about the treatment @ <\/span>Epilepsy Treatment Guidelines<\/strong><\/a><\/p>\n Epilepsy Pipeline Analysis: Drug Profiles<\/strong><\/p>\n XEN496: Xenon Pharmaceuticals Inc.<\/strong><\/p>\n Product Details<\/strong><\/p>\n XEN496 is a Kv7 potassium channel modulator that contains the active ingredient ezogabine. Xenon Pharmaceutical has begun a Phase III trial of XEN496 for the treatment of pediatric epilepsy. <\/span><\/p>\n Phase III<\/strong><\/p>\n NCT04639310: <\/strong>In March 2021, Xenon Pharmaceuticals Inc. began a randomized, Phase III trial to compare the anti-seizure effects of XEN496 (ezogabine) to placebo in children with KCNQ2 Developmental and Epileptic Encephalopathy (KCNQ2-DEE).<\/span><\/p>\n Epilepsy Pipeline Therapies and Key Companies<\/strong><\/p>\n For further information on the upcoming therapies, visit <\/span>Epilepsy Drug Pipeline<\/strong><\/a><\/p>\n Epilepsy Therapeutics Assessment<\/strong><\/p>\n Scope of the Report<\/strong><\/a><\/p>\n Coverage:<\/strong> Global<\/span><\/p>\n Epilepsy Key Players: <\/strong>Xenon Pharmaceuticals Inc., Marinus Pharmaceuticals, Cerebral Therapeutics LLC, Otsuka Pharmaceutical Co., Ltd.,<\/span> among others<\/span><\/p>\n Epilepsy Pipeline Therapies:<\/strong> XEN496, Ganaxolone, CT-010, OPC-214870,<\/span> and others<\/span><\/p>\n Table of Contents<\/strong><\/p>\n Know more about what’s covered in the <\/span>Epilepsy Assessment Report<\/strong><\/a><\/p>\n Key questions answered in the Epilepsy Pipeline Report<\/strong><\/p>\n![\"Epilepsy-Pipeline-Insights\"](\"https:\/\/beta-kiosk.icrowdnewswire.com\/assets\/source\/users\/delveinsight\/Epilepsy-Pipeline-Insights.jpg?1633342294555\" "\\"Epilepsy")
<\/span><\/p>\n\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n\n
\n 1.<\/td>\n Introduction<\/span><\/td>\n<\/tr>\n \n 2.<\/td>\n Executive Summary<\/span><\/td>\n<\/tr>\n \n 3.<\/td>\n Epilepsy: Overview<\/span><\/td>\n<\/tr>\n \n 4.<\/td>\n Epilepsy- Analytical Perspective In-depth Commercial Assessment<\/span><\/td>\n<\/tr>\n \n 5.<\/td>\n Epilepsy Pipeline Therapeutics<\/span><\/td>\n<\/tr>\n \n 6.<\/td>\n Epilepsy Late Stage Products (Phase III)<\/span><\/td>\n<\/tr>\n \n 7.<\/td>\n Epilepsy Late Stage Products (Phase II\/III)<\/span><\/td>\n<\/tr>\n \n 8.<\/td>\n Epilepsy Mid Stage Products (Phase II)<\/span><\/td>\n<\/tr>\n \n 9.<\/td>\n Epilepsy Early Stage Products (Phase I)<\/span><\/td>\n<\/tr>\n \n 10.<\/td>\n Epilepsy Therapeutic Assessment<\/span><\/td>\n<\/tr>\n \n 11.<\/td>\n Epilepsy Inactive Products<\/span><\/td>\n<\/tr>\n \n 12.<\/td>\n Epilepsy Company-University Collaborations (Licensing\/Partnering) Analysis<\/span><\/td>\n<\/tr>\n \n 13.<\/td>\n Epilepsy Key Companies<\/span><\/td>\n<\/tr>\n \n 14.<\/td>\n Epilepsy Key Products<\/span><\/td>\n<\/tr>\n \n 15.<\/td>\n Epilepsy- Unmet Needs<\/span><\/td>\n<\/tr>\n \n 16.<\/td>\n Epilepsy- Market Drivers and Barriers<\/span><\/td>\n<\/tr>\n \n 17.<\/td>\n Epilepsy- Future Perspectives and Conclusion<\/span><\/td>\n<\/tr>\n \n 18.<\/td>\n Epilepsy Analyst Views<\/span><\/td>\n<\/tr>\n \n 19.<\/td>\n Appendix<\/span><\/td>\n<\/tr>\n \n 20.<\/td>\n About DelveInsight<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n